Thinking of conducting clinical trials in Asia?
Certainly more and more pharmaceutical companies are, and with good reason. The predominantly secondary healthcare environment, treatment-naïve patients and large population can mean less time to recruit and faster clinical development. Data quality is high, there are fewer competing studies, and the presence of large hospitals means more patients per site and dramatically reduced trial costs. But jumping on the Asian bandwagon without the proper forethought and knowledge could turn your trial into a tribulation
This audio conference is presented by Anthony Bishop, Quintiles East Asia. For more details, please visit our site www.fxconferences.com
